Biblio Discovery — Demo Discovery Service

17 hasil untuk "Daniel Breadner"

Menampilkan 1–17 · 0,53 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment

    Saqib Raza Khan; Daniel Breadner

    Current Oncology, Vol. 32 No. 4 · 2025 · Inggris · DOAJ Scopus

    Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of the cases. Despite advancements in targeted therapies and immunotherapies, many patients still rely on chemotherapy, highlighting the need for…

  2. Artikel Jurnal Teks lengkap

    ‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review

    Saurav Verma; Daniel Breadner; Jacques Raphael

    Current Oncology, Vol. 30 No. 4 · 2023 · Inggris · DOAJ Scopus

    Antibody-Drug conjugates (ADCs) are a relatively new class of drugs with a promise to improve the outcomes in specific cancers. By delivering the cytotoxic agent to tumor cells expressing specific antigens, ADCs achieve a better therapeutic index and more potency. ADCs have been approved for…

  3. Artikel Jurnal Teks lengkap

    A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer

    Saqib Raza Khan; Enxhi Kotrri; Daniel Breadner dkk.

    Current Oncology, Vol. 33 No. 1 · 2025 · Inggris · DOAJ Scopus

    The management strategies in resectable non-small cell lung cancer (NSCLC) have changed over the last few years. Despite advancements in surgical techniques and conventional chemotherapy, patients with resectable NSCLC remained at high risk of future recurrence. Clinical trials have demonstrated…

  4. Artikel Jurnal

    The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer

    Saurav Verma; Sympascho Young; Alexander V. Louie dkk.

    Therapeutic Advances in Medical Oncology, Vol. 15 · 2023 · Inggris · DOAJ Scopus

    The improvement in treatment strategies and outcomes in small cell lung cancer (SCLC) has lagged behind other cancers. The addition of immune checkpoint inhibitors (ICIs), durvalumab and atezolizumab, to the platinum-based chemotherapy in frontline setting has improved the survival in extensive…

  5. Artikel Jurnal

    Antibody–drug conjugates versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

    Saqib Raza Khan; Laís Marques Eiras; Gabriel Boldt dkk.

    Therapeutic Advances in Medical Oncology, Vol. 17 · 2025 · Inggris · DOAJ Scopus

    Background: Docetaxel, following progression on immunotherapy and platinum-based chemotherapy, remains the standard of care for advanced non-small-cell lung cancer (NSCLC) but offers limited promise. Antibody–drug conjugates (ADCs) may improve outcomes in this population. Objectives: Data from the…

  6. Artikel Jurnal

    A Rare Association of Mixed Autoimmune Hemolytic Anemia with Gastric Carcinoma

    Anu Chinnadurai; Scott Strum; Artin Ghassemian dkk.

    Case Reports in Oncology, Vol. 16 No. 1 · 2023 · Inggris · DOAJ Scopus

    This case report outlines a 70-year-old female patient who presented with a concurrent mixed autoimmune hemolytic anemia (AIHA) and a gastric adenocarcinoma. Her treatment course of these two diseases is summarized, which included supportive care, neoadjuvant chemotherapy for her gastric…

  7. Artikel Jurnal Teks lengkap

    Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions

    Angel Kwan Qi Wong; Saqib Raza Khan; Danial Khan Hadi dkk.

    Current Oncology, Vol. 33 No. 1 · 2026 · Inggris · DOAJ Scopus

    Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers with adenocarcinoma being the most common subtype. Patients with stage IV NSCLC typically have poor prognosis. In these patients, identification of actionable genomic alterations allows for the selection of targeted…

  8. Artikel Jurnal

    Skin Deep: A Fascinating Case Report of Immunotherapy-Triggered, Treatment-Refractory Autoimmune Lichen Planus and Keratoacanthoma

    Beatrice T. B. Preti; Alec Pencz; Jeffery J. M. Cowger dkk.

    Case Reports in Oncology, Vol. 14 No. 2 · 2021 · Inggris · DOAJ Scopus

    This case discusses a 62-year-old woman with de novo metastatic lung adenocarcinoma (PD-L1 >50% with a KRAS G12C mutation, ALK and EGFR negative) who was on pembrolizumab for 1 year without any significant toxicity, only low-grade dermatitis and hypothyroidism. She was transitioned to pembrolizumab…

  9. Artikel Jurnal

    Assessing clinician performance using a multi-modality clinical decision-support system for lung cancer prognostication

    Jaryd R. Christie; Karen Eddy; Richard A. Malthaner dkk.

    Scientific Reports, Vol. 16 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Surgery is the primary treatment for early-stage lung cancer. Adjuvant therapy is offered to patients who are at a high risk of recurrence, however, determining the patients that would benefit from additional therapy is often difficult. In this study, we aimed to develop a clinical…

  10. Artikel Jurnal

    The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis

    Daniel Breadner; Jonathan M. Loree; Winson Y. Cheung dkk.

    BMC Cancer, Vol. 22 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract Background Colorectal cancer remains the second leading cause of cancer death in North America. Fluorouracil and oxaliplatin based adjuvant chemotherapy for resected colon cancer (CC) reduces cancer recurrence, but also causes significant toxicity requiring dose reductions. The effect of…

  11. Artikel Jurnal Teks lengkap

    Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer

    Beatrice T. B. Preti; Michael S. Sanatani; Daniel Breadner dkk.

    Current Oncology, Vol. 30 No. 8 · 2023 · Inggris · DOAJ Scopus

    The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly from real-world populations, which can have…

  12. Artikel Jurnal Teks lengkap

    Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective

    Daniel Breadner; David M. Hwang; Don Husereau dkk.

    Current Oncology, Vol. 31 No. 10 · 2024 · Inggris · DOAJ Scopus

    Lung cancer is the leading cause of cancer-related deaths in Canada, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Timely access to comprehensive molecular profiling is critical for selecting biomarker-matched targeted therapies, which lead to improved outcomes in…

  13. Artikel Jurnal

    Circulating tumor DNA as part of the routine work-up for patients with suspected advanced lung cancer

    Emma Holjak; Tia Brasoveanu; Saurav Verma dkk.

    The Journal of Liquid Biopsy, Vol. 10 · 2025 · Inggris · DOAJ Scopus

    Liquid biopsy (LB) is a useful tool in patients with advanced non-small cell lung cancer (aNSCLC) to detect actionable molecular alterations and thereby allow genotype-matched therapies. Currently, LB is recommended for individuals diagnosed with aNSCLC who have an insufficient tissue sample or…

  14. Artikel Jurnal Teks lengkap

    Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies

    Parneet K. Cheema; Kirstin A. Perdrizet; Randeep S. Sangha dkk.

    Current Oncology, Vol. 33 No. 2 · 2026 · Inggris · DOAJ Scopus

    As bispecific T-cell engagers (TCEs) gain traction in the oncology treatment landscape, cancer centres must develop robust clinical pathways to ensure their safe and efficient delivery. Given the limited experience of the Canadian medical oncology community with TCEs, collecting and publishing…

  15. Artikel Jurnal

    Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort

    Saurav Verma; Amanda Chapman; Lee-Anne Pickard dkk.

    Exploration of Targeted Anti-tumor Therapy, Vol. 5 No. 5 · 2024 · Inggris · DOAJ Scopus

    Aim: Human epidermal growth factor receptor-2 (HER2) is a well-established prognostic and predictive biomarker. It is an FDA-approved therapeutic target for HER2 positive breast, gastroesophageal, and more recently, lung and colon cancers. It is an emerging biomarker in biliary tract, bladder…

  16. Artikel Jurnal Teks lengkap

    Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors

    Anna Lapuk; Benjamin L. S. Furman; Pedro Feijao dkk.

    Current Oncology, Vol. 33 No. 1 · 2025 · Inggris · DOAJ Scopus

    Personalized cancer treatment depends on the accurate and timely detection of the patient tumor variants. LBx enables minimally invasive tumor mutation profiling. We report results of a pan-Canadian LBx program for patients with advanced solid tumors. Plasma samples were tested at Imagia Canexia…

  17. Artikel Jurnal

    Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory

    Pratibha Bhai; Jacob Turowec; Stephanie Santos dkk.

    Frontiers in Oncology, Vol. 13 · 2023 · Inggris · DOAJ Scopus

    BackgroundPersonalized targeted therapies have transformed management of several solid tumors. Timely and accurate detection of clinically relevant genetic variants in tumor is central to the implementation of molecular targeted therapies. To facilitate precise molecular testing in solid tumors…